PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22358108-3	2011	The effect of simvastatin on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 activity was evaluated.	Simvastatin	14-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-43	
10464145-12	1999	mdr1b mRNA levels were moderately increased in both simvastatin-fed groups.	Simvastatin	52-63	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-5	
22358108-3	2011	The effect of simvastatin on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 activity was evaluated.	Simvastatin	14-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-49	
20166433-10	2009	These results implied that simvastatin significantly enhanced the oral bioavailability of verapamil by inhibiting the CYP3A-mediated metabolism in small intestine or in the liver and P-glycoprotein (P-gp) efflux pump in small intestine.	Simvastatin	27-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	183-197	
20166433-10	2009	These results implied that simvastatin significantly enhanced the oral bioavailability of verapamil by inhibiting the CYP3A-mediated metabolism in small intestine or in the liver and P-glycoprotein (P-gp) efflux pump in small intestine.	Simvastatin	27-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	199-203